PsyRx News
6 articles
PSYRX'S INNOVATIVE NEXT-GENERATION- PLANT-BASED SOLUTION FOR DEPRESSION
PsyRx, a Rehovot-based company, is developing natural pharmaceutical-grade psychedelics for mental health therapeutics. The company is working on a medication that combines ibogaine, a substance derived from the Tabernanthe Iboga plant, with an approved SSRI anti-depressant. The company believes this combination will be more effective and have fewer side effects than existing antidepressants. PsyRx is also investigating the therapeutic potential of psilocybin, sourced from hallucinogenic mushrooms. The company is currently conducting a Series C financing round through the online equity-based crowd-investing platform ExitValley, with TrippyVC being a major investor.
InvestmentExpand
PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board
PsyRx Ltd, a pharmaceutical company specializing in drug discovery for mental health conditions, has appointed Professor Itamar Grotto as its Executive Chairman. This follows the recent renewal of the companys license to conduct R&D in Psilocybin and Ibogaine by the Israeli Ministry of Health. Prof. Grotto, a Public Health Physician and Professor of Epidemiology, has previously served as the Director of Public Health Services and the Associate Director General at the Israeli Ministry of Health. He was also a member of the Executive Board of the World Health Organization.
Management Changes
https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925
PsyRx, an Israel-based pharmaceutical company, has announced the appointment of Prof. Itamar Grotto as the new Executive Chairman of their scientific advisory board. Prof. Grotto was the former Associate Director-General of the Health Ministry between 2017 and 2021, a Public Health Physician and Professor of Epidemiology, and a WHO Executive Board Member. The company focuses on treating mental health conditions by producing and researching GMP-grade Psilocybin and Ibogaine for drug purposes.
Management Changes
Now psychedelics are coming to your medicine cabinet
PsyRx, an Israeli company, is developing standardized pharma-grade psychedelics from natural sources to treat mental health issues. The company uses an agro-medical bioreactor to produce psychedelic botanic extracts psilocybin and ibogaine, which have shown positive effects in treating depression, anxiety, addiction, and other conditions. PsyRx is focusing on the potential of ibogaine to improve current SSRI antidepressants. The company is planning to start small animal trials soon to check safety and efficacy, with hopes to start human trials in a year. PsyRx has raised a couple of million dollars from private investors and plans to go public.
InvestmentExpand
חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע
Israeli company PsyRx is developing innovative drugs for the treatment of depression and addiction. The companys vision is to develop a new drug composed of a combination of an existing drug with extracts from mushrooms and the root of the iboga plant. The company is working on the development of intellectual property of growth and extraction methods of the iboga root and psilocybin, for use as raw materials in drugs through bio-reactors. The company initially will only produce the raw materials for other companies that will register the products as drugs. The process is in its most advanced stages and has even received significant financial investment.
Investment
https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524
Israeli pharmaceutical R&D company, PsyRx, is developing psilocybin and other biological psychoactive compounds using biological bioreactor technology. The companys main focus is on depression and addiction treatment. It also manufactures high-standard ibogaine, a psychoactive alkaloid effective in reducing addiction severity. The companys bioreactor allows it to grow more sterile and consistent compounds than would be possible in nature. PsyRx has completed its initial goals of growing psilocybin on solid and liquid surfaces and has begun its prior-to-submission phase to the FDA for approval to test an Ibogaine-based micro-dosed antidepressant drug.
InvestmentExpand
